{"id":"met","name":"MET","symbol":"MET","route":"/targets/met/","asOf":"2026-09-04","xrefs":[{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7029","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000105976","uniprot":"https://www.uniprot.org/uniprotkb/P08581/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/P08581","chembl":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL3717","open-targets":"https://platform.opentargets.org/target/ENSG00000105976","civic":"https://civicdb.org/genes/4233/summary","oncokb":"https://www.oncokb.org/gene/MET","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=MET","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=MET","depmap":"https://depmap.org/portal/gene/MET?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000105976-MET","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/4233","omim":"https://www.omim.org/entry/164860"}],"products":[{"id":"al2846","name":"AL2846","status":"phase-3","modality":"small molecule (structure undisclosed or not yet in PubChem)","route":"/drugs/al2846/"},{"id":"amivantamab","name":"Amivantamab","status":"approved","modality":"Bispecific antibody (EGFR×MET)","route":"/drugs/amivantamab/"},{"id":"bezuclastinib","name":"Bezuclastinib","status":"phase-3","modality":"small molecule","route":"/drugs/bezuclastinib/"},{"id":"cabozantinib","name":"Cabozantinib","status":"approved","modality":"Small-molecule multi-kinase inhibitor (MET, VEGFR2, AXL, RET)","route":"/drugs/cabozantinib/"},{"id":"capmatinib","name":"Capmatinib","status":"approved","modality":"Small-molecule MET tyrosine kinase inhibitor","route":"/drugs/capmatinib/"},{"id":"capmatinib-tepotinib","name":"Capmatinib & tepotinib","status":"approved","modality":"Small-molecule kinase inhibitors (MET)","route":"/drugs/capmatinib-tepotinib/"},{"id":"crizotinib","name":"Crizotinib","status":"approved","modality":"Small-molecule ALK/ROS1/MET TKI (first generation)","route":"/drugs/crizotinib/"},{"id":"glumetinib","name":"Glumetinib","status":"approved","modality":"Oral selective MET tyrosine kinase inhibitor","route":"/drugs/glumetinib/"},{"id":"guardant360-cdx","name":"Guardant360 CDx","status":"approved","modality":"Liquid biopsy companion diagnostic test (NGS, cfDNA)","route":"/drugs/guardant360-cdx/"},{"id":"hdm2017","name":"HDM2017","status":"phase-2","modality":"not stated (registered as a drug or biological on ClinicalTrials.gov)","route":"/drugs/hdm2017/"},{"id":"hs-20117","name":"HS-20117","status":"phase-3","modality":"bispecific antibody","route":"/drugs/hs-20117/"},{"id":"js111","name":"JS111","status":"phase-2","modality":"small molecule (structure undisclosed or not yet in PubChem)","route":"/drugs/js111/"},{"id":"lam561","name":"LAM561","status":"phase-3","modality":"small molecule","route":"/drugs/lam561/"},{"id":"mcla-129","name":"MCLA-129","status":"phase-2","modality":"bispecific antibody","route":"/drugs/mcla-129/"},{"id":"savolitinib","name":"Savolitinib","status":"approved","modality":"Small-molecule selective MET TKI","route":"/drugs/savolitinib/"},{"id":"telisotuzumab-vedotin","name":"Telisotuzumab vedotin","status":"approved","modality":"ADC","route":"/drugs/telisotuzumab-vedotin/"},{"id":"tepotinib","name":"Tepotinib","status":"approved","modality":"Small-molecule MET tyrosine kinase inhibitor","route":"/drugs/tepotinib/"},{"id":"tilatamig-samrotecan","name":"Tilatamig samrotecan","status":"phase-2","modality":"Bispecific ADC","route":"/drugs/tilatamig-samrotecan/"},{"id":"tqb2922","name":"TQB2922","status":"phase-2","modality":"bispecific antibody","route":"/drugs/tqb2922/"},{"id":"tqb6411","name":"TQB6411","status":"phase-2","modality":"ADC","route":"/drugs/tqb6411/"},{"id":"vebreltinib","name":"Vebreltinib","status":"approved","modality":"Oral selective MET tyrosine kinase inhibitor","route":"/drugs/vebreltinib/"},{"id":"zanzalintinib","name":"Zanzalintinib","status":"phase-3","modality":"small molecule","route":"/drugs/zanzalintinib/"}],"trials":[{"id":"nct04586231","name":"LITESPARK-011","nct":"NCT04586231","phase":"3","status":"positive"},{"id":"nct04988295","name":"A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure","nct":"NCT04988295","phase":"3","status":"active"},{"id":"nct04446117","name":"Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC","nct":"NCT04446117","phase":"3","status":"active"},{"id":"nct03755791","name":"Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Rece","nct":"NCT03755791","phase":"3","status":"active"},{"id":"nct04538664","name":"A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions","nct":"NCT04538664","phase":"3","status":"active"},{"id":"cabinet","name":"CABINET (Alliance A021602)","nct":"NCT03375320","phase":"3","status":"positive"},{"id":"nct03690388","name":"A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Va","nct":"NCT03690388","phase":"3","status":"active"},{"id":"contact-03","name":"CONTACT-03","nct":"NCT04338269","phase":"3","status":"negative"},{"id":"mariposa","name":"MARIPOSA","nct":"NCT04487080","phase":"3","status":"positive"},{"id":"cosmic-313","name":"COSMIC-313","nct":"NCT03937219","phase":"3","status":"mixed"},{"id":"nct02767804","name":"eXalt3","nct":"NCT02767804","phase":"3","status":"positive"},{"id":"checkmate-9er","name":"CheckMate 9ER","nct":"NCT03141177","phase":"3","status":"positive"},{"id":"nct03091192","name":"Savolitinib vs. Sunitinib in MET-driven PRCC.","nct":"NCT03091192","phase":"3","status":"active"},{"id":"alesia","name":"ALESIA","nct":"NCT02838420","phase":"3","status":"positive"},{"id":"alta-1l","name":"ALTA-1L","nct":"NCT02737501","phase":"3","status":"positive"},{"id":"celestial","name":"CELESTIAL","nct":"NCT01908426","phase":"3","status":"positive"},{"id":"alex","name":"ALEX","nct":"NCT02075840","phase":"3","status":"positive"},{"id":"j-alex","name":"J-ALEX","phase":"3","status":"positive"},{"id":"comet-1","name":"COMET-1","nct":"NCT01605227","phase":"3","status":"negative"},{"id":"profile-1014","name":"PROFILE 1014","nct":"NCT01154140","phase":"3","status":"positive"},{"id":"exam","name":"EXAM","nct":"NCT00704730","phase":"3","status":"positive"},{"id":"nct05208047","name":"(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors","nct":"NCT05208047","phase":"3","status":"recruiting"},{"id":"nct07489495","name":"A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)","nct":"NCT07489495","phase":"3","status":"recruiting"},{"id":"nct07227402","name":"A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)","nct":"NCT07227402","phase":"3","status":"recruiting"},{"id":"nct05989542","name":"A Confirmatory Clinical Study in NSCLC Patients With MET Exon 14 Mutation (KUNPENG-2)","nct":"NCT05989542","phase":"3","status":"recruiting"},{"id":"nct06564324","name":"A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients","nct":"NCT06564324","phase":"3","status":"recruiting"},{"id":"nct06860971","name":"A Study of AL2846 Capsule Versus Placebo in the Treatment of Advanced Radioiodine-Refractory Differentiated Thyroid Carcinoma","nct":"NCT06860971","phase":"3","status":"recruiting"},{"id":"nct06750094","name":"A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy","nct":"NCT06750094","phase":"3","status":"recruiting"},{"id":"nct06662786","name":"A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer","nct":"NCT06662786","phase":"3","status":"recruiting"},{"id":"nct07276399","name":"A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer","nct":"NCT07276399","phase":"3","status":"recruiting"},{"id":"nct03729245","name":"A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)","nct":"NCT03729245","phase":"3"},{"id":"nct06140836","name":"A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)","nct":"NCT06140836","phase":"3","status":"active"},{"id":"nct06930794","name":"A Study of Vebreltinib and Platinum-Containing Double Agents in Subjects With MET-Positive","nct":"NCT06930794","phase":"3","status":"recruiting"},{"id":"nct04603807","name":"A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases","nct":"NCT04603807","phase":"3","status":"active"},{"id":"nct06829459","name":"A Study to Evaluate the Efficacy and Safety of Glumetinib Combined With Osimertinib Mesylate Versus Platinum-based Doublet Chemotherapy in N","nct":"NCT06829459","phase":"3","status":"recruiting"},{"id":"nct05009836","name":"Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC","nct":"NCT05009836","phase":"3","status":"active"},{"id":"nct07405164","name":"Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)","nct":"NCT07405164","phase":"3","status":"recruiting"},{"id":"nct07620574","name":"Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study","nct":"NCT07620574","phase":"3","status":"recruiting"},{"id":"nct03784014","name":"Molecular Profiling of Advanced Soft-tissue Sarcomas","nct":"NCT03784014","phase":"3","status":"completed"},{"id":"nct05043090","name":"Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC","nct":"NCT05043090","phase":"3","status":"active"},{"id":"nct05261399","name":"Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment","nct":"NCT05261399","phase":"3","status":"active"},{"id":"nct04632758","name":"Study Comparing WX-0593 to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients","nct":"NCT04632758","phase":"3"},{"id":"nct07011719","name":"Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma","nct":"NCT07011719","phase":"3","status":"recruiting"},{"id":"nct05425940","name":"Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer","nct":"NCT05425940","phase":"3","status":"active"},{"id":"telimet-nsclc-01","name":"TeliMET NSCLC-01","nct":"NCT04928846","phase":"3","status":"recruiting"},{"id":"nct06908993","name":"Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated","nct":"NCT06908993","phase":"3","status":"recruiting"},{"id":"nct06970782","name":"Vebreltinib Plus PLB1004 Versus Platinum-based Doublet Chemotherapy in Patients With EGFRm, MET+, Locally Advanced or Metastatic NSCLC Following EGFR-TKI Failur","nct":"NCT06970782","phase":"3","status":"planned"},{"id":"nct07750158","name":"Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual Disease","nct":"NCT07750158","phase":"3","status":"recruiting"},{"id":"nct06417008","name":"A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer","nct":"NCT06417008","phase":"2/3","status":"recruiting"},{"id":"nct06105619","name":"A Study of PLB1001 Enteric Capsules in the Treatment of sGBM/IDH Mutant Glioblastoma Patients With the ZM Fusion Gene (FUGEN).","nct":"NCT06105619","phase":"2/3","status":"active"},{"id":"nct05987332","name":"IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma","nct":"NCT05987332","phase":"2/3","status":"active"},{"id":"nct04250922","name":"LAM561 With RT and TMZ for Adults With Glioblastoma","nct":"NCT04250922","phase":"2/3","status":"active"},{"id":"nct06082167","name":"Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","nct":"NCT06082167","phase":"2/3","status":"active"},{"id":"nct06943755","name":"Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors","nct":"NCT06943755","phase":"2/3","status":"recruiting"},{"id":"lung-map","name":"Lung-MAP (SWOG S1400 and S1900)","nct":"NCT02154490","phase":"platform","status":"completed"},{"id":"nci-match","name":"NCI-MATCH (EAY131)","nct":"NCT02465060","phase":"platform","status":"active"},{"id":"alchemist","name":"ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials)","nct":"NCT02194738","phase":"platform","status":"active"},{"id":"nct03778229","name":"Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib","nct":"NCT03778229","phase":"2","status":"active"},{"id":"nct05663866","name":"Premedication to Reduce Amivantamab Associated Infusion Related Reactions","nct":"NCT05663866","phase":"2","status":"active"},{"id":"nct04606771","name":"A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLC","nct":"NCT04606771","phase":"2","status":"active"},{"id":"nct02159066","name":"LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma","nct":"NCT02159066","phase":"2","status":"completed"},{"id":"luminosity","name":"LUMINOSITY","nct":"NCT03539536","phase":"2","status":"positive"},{"id":"papmet","name":"PAPMET (SWOG S1500)","nct":"NCT02761057","phase":"2","status":"positive"},{"id":"cabone","name":"CABONE","nct":"NCT02243605","phase":"2","status":"positive"},{"id":"geometry-mono-1","name":"GEOMETRY mono-1","nct":"NCT02414139","phase":"2","status":"positive"},{"id":"national-lung-matrix-trial","name":"National Lung Matrix Trial","nct":"NCT02664935","phase":"2","status":"completed"},{"id":"tapur","name":"TAPUR (Targeted Agent and Profiling Utilization Registry)","nct":"NCT02693535","phase":"2","status":"recruiting"},{"id":"nct02864992","name":"VISION (tepotinib)","nct":"NCT02864992","phase":"2","status":"positive"},{"id":"nct04996875","name":"(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis","nct":"NCT04996875","phase":"2","status":"recruiting"},{"id":"nct05186753","name":"(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis","nct":"NCT05186753","phase":"2","status":"active"},{"id":"nct06667076","name":"A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)","nct":"NCT06667076","phase":"2","status":"recruiting"},{"id":"nct05498428","name":"A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer","nct":"NCT05498428","phase":"2","status":"recruiting"},{"id":"nct05859217","name":"A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1)","nct":"NCT05859217","phase":"2","status":"planned"},{"id":"nct07586202","name":"A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC","nct":"NCT07586202","phase":"2","status":"recruiting"},{"id":"nct06568939","name":"A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult ","nct":"NCT06568939","phase":"2","status":"recruiting"},{"id":"nct05801029","name":"A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth","nct":"NCT05801029","phase":"2","status":"active"},{"id":"nct03634540","name":"A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)","nct":"NCT03634540","phase":"2","status":"active"},{"id":"nct03175224","name":"APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors","nct":"NCT03175224","phase":"2","status":"recruiting"},{"id":"nct01639508","name":"Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or A","nct":"NCT01639508","phase":"2","status":"recruiting"},{"id":"nct06120140","name":"Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib","nct":"NCT06120140","phase":"2","status":"active"},{"id":"nct07677579","name":"NIMBLE-CRC: NeoImmunoModulation Before Leveraging Excision in Colorectal Rectal Cancer","nct":"NCT07677579","phase":"2","status":"planned"},{"id":"nct03899155","name":"Pan Tumor Rollover Study","nct":"NCT03899155","phase":"2","status":"recruiting"},{"id":"nct03944772","name":"Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)","nct":"NCT03944772","phase":"2","status":"active"},{"id":"nct05845450","name":"Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)","nct":"NCT05845450","phase":"2","status":"recruiting"},{"id":"nct06947291","name":"Safety and Efficacy of Glumetinib Combined With Docetaxel for Injection (Albumin-bound) in Patients With Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors","nct":"NCT06947291","phase":"2","status":"recruiting"},{"id":"nct05374603","name":"Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLC","nct":"NCT05374603","phase":"2","status":"active"},{"id":"nct06885840","name":"Study of MCLA-129 in the Treatment of Advanced Non-small Cell Lung Cancer with AGA and MET Amplification.","nct":"NCT06885840","phase":"2","status":"planned"},{"id":"nct03040973","name":"Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone","nct":"NCT03040973","phase":"2","status":"active"},{"id":"nct05725200","name":"Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer","nct":"NCT05725200","phase":"2","status":"recruiting"},{"id":"nct07323641","name":"Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer","nct":"NCT07323641","phase":"2","status":"recruiting"},{"id":"nct06574347","name":"Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.","nct":"NCT06574347","phase":"2","status":"recruiting"},{"id":"nct07367529","name":"A Clinical Trial on the Efficacy and Safety of TQB6411 for Injection","nct":"NCT07367529","phase":"1/2","status":"recruiting"},{"id":"nct07439094","name":"A First-in-Human Study of CKD-703 in Advanced Solid Tumors and Non-Small Cell Lung Cancer","nct":"NCT07439094","phase":"1/2","status":"recruiting"},{"id":"nct07621159","name":"A Phase Ib/II Study of HDM2017 in Combination With Standard of Care in Advanced Colorectal Cancer","nct":"NCT07621159","phase":"1/2","status":"planned"},{"id":"nct06385080","name":"A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer","nct":"NCT06385080","phase":"1/2","status":"recruiting"},{"id":"nct05488314","name":"A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer","nct":"NCT05488314","phase":"1/2","status":"active"},{"id":"nct07227025","name":"A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer","nct":"NCT07227025","phase":"1/2","status":"recruiting"},{"id":"nct05379595","name":"A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer","nct":"NCT05379595","phase":"1/2","status":"recruiting"},{"id":"nct05908734","name":"A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer","nct":"NCT05908734","phase":"1/2","status":"active"},{"id":"nct07805551","name":"A Study of HDM2017 Combination Therapy in Advanced Colorectal Cancer","nct":"NCT07805551","phase":"1/2","status":"recruiting"},{"id":"nct07208149","name":"A Study of MR001 in Patients With Locally Recurrent or Metastatic Advanced Triple-Negative Breast Cancer (TNBC)","nct":"NCT07208149","phase":"1/2","status":"recruiting"},{"id":"nct07293351","name":"A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal ","nct":"NCT07293351","phase":"1/2","status":"recruiting"},{"id":"nct04270591","name":"Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer","nct":"NCT04270591","phase":"1/2","status":"recruiting"},{"id":"nct03539822","name":"Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies","nct":"NCT03539822","phase":"1/2","status":"recruiting"},{"id":"nct07367516","name":"Clinical Trial Evaluating TQB6411 Injection in Participant s With Esophageal Cancer","nct":"NCT07367516","phase":"1/2","status":"recruiting"},{"id":"nct06669117","name":"FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations","nct":"NCT06669117","phase":"1/2","status":"recruiting"},{"id":"nct06940401","name":"JS111 in Patients With Advanced NSCLC Harboring EGFR Mutations","nct":"NCT06940401","phase":"1/2","status":"active"},{"id":"nct04868877","name":"Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combina","nct":"NCT04868877","phase":"1/2","status":"active"},{"id":"nct03947385","name":"Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions","nct":"NCT03947385","phase":"1/2","status":"recruiting"},{"id":"nct04299191","name":"Study of LAM561 Acid in Pediatric Patients With Malignant Glioma and Other Advanced Solid Tumors","nct":"NCT04299191","phase":"1/2","status":"recruiting"},{"id":"nct07448116","name":"Study of MCLA-129 in Combination With Ensartinib in Patients With Advanced Solid Tumors.","nct":"NCT07448116","phase":"1/2","status":"recruiting"},{"id":"nct04930432","name":"Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors","nct":"NCT04930432","phase":"1/2","status":"recruiting"},{"id":"nct07049926","name":"Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (","nct":"NCT07049926","phase":"1/2","status":"recruiting"},{"id":"nct07044908","name":"TQB2922 and TAS-102 Tablets for Injection With or Without Bevacizumab in Chemotherapy-failed RAS/BRAF Wild-type Advanced Colorectal Cancer","nct":"NCT07044908","phase":"1/2","status":"recruiting"},{"id":"nct07655622","name":"Vebreltinib Plus Furmonertinib in Patients With EGFR-mutated Advanced Non-small Cell Lung Cancer and High PD-L1 Expression","nct":"NCT07655622","phase":"1/2","status":"recruiting"},{"id":"nct06343064","name":"Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI","nct":"NCT06343064","phase":"1/2","status":"recruiting"},{"id":"chrysalis","name":"CHRYSALIS","nct":"NCT02609776","phase":"1","status":"active"},{"id":"profile-1001-ros1","name":"PROFILE 1001 ROS1 expansion cohort","nct":"NCT00585195","phase":"1","status":"positive"},{"id":"nct05647122","name":"First in Human Study of AZD9592 in Solid Tumors","nct":"NCT05647122","phase":"1","status":"active"}],"pathways":["hepatocellular-carcinoma-signalling","nsclc-signalling","rtk-activation","renal-cell-carcinoma-signalling","resistance-routes-map"],"companies":["abbvie","apollomics","astrazeneca","avistone-biotechnology","betta","cogent-biosciences","exelixis","genmab","guardant-health","haihe-biopharma","hansoh-pharma","hutchmed","imagene-ai","ipsen","johnson-johnson","laminar-pharmaceuticals","lucence","merck","merck-kgaa","mythic-therapeutics","novartis","pathos-ai","pfizer","junshi","sino-biopharm"],"keyPapers":["paper-mariposa-nejm-2024","paper-philip-kras-wild-type-pancreatic-ccr-2022","paper-zhang-lung-cancer-never-smokers-nat-genet-2021","paper-wolf-geometry-mono-1-capmatinib-nejm-2020","paper-aggarwal-plasma-genotyping-personalised-therapy-jama-oncol-2019","paper-leighl-nile-cfdna-tissue-genotyping-ccr-2019","paper-oxnard-osimertinib-resistance-mechanisms-jama-oncol-2018","paper-lindeman-lung-molecular-testing-guideline-jto-2018","paper-jordan-prospective-lung-adenocarcinoma-msk-cancer-discov-2017","paper-tracerx-100-nejm-2017","paper-awad-met-exon-14-mutations-lung-jco-2016","paper-frampton-met-exon-14-cancer-discov-2015","paper-tcga-lung-adenocarcinoma-nature-2014","paper-kris-lung-cancer-mutation-consortium-jama-2014","paper-yu-acquired-resistance-rebiopsy-egfr-ccr-2013","paper-sequist-genotypic-histological-evolution-egfr-resistance-sci-transl-med-2011","paper-kwak-crizotinib-alk-nsclc-nejm-2010","paper-lemmon-schlessinger-rtk-signalling-cell-2010","paper-engelman-met-amplification-gefitinib-resistance-science-2007"],"hotspots":[{"label":"Exon 14 skipping (splice sites around D1010, Y1003)","position":1003,"kind":"activating","frequency":"About 3% of NSCLC","drugs":["capmatinib-tepotinib","crizotinib","amivantamab"]},{"label":"D1228N/H and Y1230C/H","position":1228,"kind":"resistance","drugs":["cabozantinib","amivantamab","telisotuzumab-vedotin"]}],"openQuestions":[{"id":"met-amplification-definition","question":"What definition of MET amplification or overexpression should select patients for MET-directed drugs at EGFR-TKI progression?","stage":"translational","actor":"regulator","source":{"label":"MARIPOSA, NEJM 2024","url":"https://doi.org/10.1056/NEJMoa2403614"}}],"assays":[{"id":"foundationone-cdx-panel","name":"FoundationOne CDx","cutoff":"Per companion claim: EGFR, ALK, BRAF V600, ERBB2 amplification, KRAS wild-type, BRCA1/2 and HRR genes, PIK3CA, MET exon 14, RET, FGFR2 fusions, IDH1, NTRK fusions; MSI-high; TMB at least 10 mutations per megabase"},{"id":"oncomine-dx","name":"Oncomine Dx Target Test","cutoff":"Per companion claim: BRAF V600E (dabrafenib plus trametinib), ROS1 fusions (crizotinib), EGFR (gefitinib), RET fusions (pralsetinib), MET exon 14 (tepotinib), EGFR exon 20 insertions"}],"resistance":[{"class":"egfr-tki","mechanism":"On-target EGFR C797S","category":"on-target"},{"class":"egfr-tki","mechanism":"MET amplification / bypass","category":"bypass"},{"class":"egfr-tki","mechanism":"Histologic transformation","category":"lineage"},{"class":"alk-tki","mechanism":"Bypass signalling (MET, EGFR, KRAS)","category":"bypass"},{"class":"kras-g12c","mechanism":"Bypass alterations (MET amplification, NRAS/BRAF mutations, RTK fusions)","category":"bypass"}],"licence":"CC BY-NC 4.0, attribution to OnCo (https://onco.cc); commercial use needs a licence"}